In this article, we will list the 5 Most Undervalued Growth Stocks to Buy According to Analysts. Please visit 9 Most Undervalued Growth Stocks to Buy According to Analysts if you would like to see the extended list and the methodology behind it.

5. Agnico Eagle Mines Limited (NYSE:AEM)

Stock Upside Potential: 41.17%

Forward P/E: 13.09

Number of Hedge Fund Holders: 56

Agnico Eagle Mines Limited (NYSE:AEM) is one of the most undervalued growth stocks to buy, according to analysts. On March 24, Erste Group downgraded Agnico Eagle Mines Limited (NYSE:AEM) stock rating to a Hold from Buy. The downgrade follows a period of underperformance that has seen the stock pull back significantly.

Agnico-Eagle Mines was one of the stocks that rallied as gold prices reached all-time highs above $5,000 an ounce. However, the precious metal has pulled back, plunging by more than 15% from all-time highs. The sell-off in the precious metal has also triggered a 10%+ pullback in the stock’s price.

According to Erste Group, Agnico-Eagle is under pressure in the short term amid changing market conditions, which are likely to affect its operating margins. The research firm has already warned that the current profit forecasts are too high, given the significant pullback in gold prices.

In its fourth quarter of 2025, the company achieved earnings per share of $2.70, better than the $2.62 per share expected, and revenues totaled $3.56 billion, exceeding the $3.42 billion expected.

Agnico Eagle Mines Limited (NYSE:AEM) is a Canadian gold producer, recognized as one of the world’s largest gold mining companies. It focuses on exploring, developing, and operating high-quality mines in low-risk jurisdictions, primarily in Canada, Australia, Finland, and Mexico, with further exploration projects in the U.S. and Colombia.

4. Super Micro Computer Inc. (NASDAQ:SMCI)

Stock Upside Potential: 42.47%

Forward P/E: 7.69

Number of Hedge Fund Holders: 39

Super Micro Computer Inc.(NASDAQ:SMCI) is one of the most undervalued growth stocks to buy, according to analysts. On March 23, Bank of America reiterated an Underperform rating on Super Micro Computer Inc.(NASDAQ:SMCI) and cut the price target to $24 from $34.

The price target cut is in response to three individuals tied to the company being indicted in the US for violating export controls. The individuals are accused of conspiring to sell servers containing restricted GPUs into China. A senior company executive has already confirmed that two employees have been placed on administrative leave and a contractor has been terminated.

While Super Micro Computer is not a defendant amid the allegations, Bank of America has warned that the developments could weigh on its reputation and operations. The investment bank has also warned that the development could lead suppliers to tighten access to key components, including GPUs, due to stricter compliance checks. In addition, there is the risk that customers will delay orders or shift contracts to Super Micro Computer rivals, including Dell and Hewlett Packard Enterprise.

Bank of America has also warned that Super Micro Computer could face margin pressure from competition, higher component costs, and increased spending.

Super Micro Computer Inc.(NASDAQ:SMCI) designs, develops, and manufactures high-performance, energy-efficient server and storage systems for data centers, cloud computing, AI, and 5G/Edge infrastructure. The company integrates new technologies, including Nvidia chips, to build custom AI-optimized servers.

3. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Stock Upside Potential: 43.46%

Forward P/E: 4.68

Number of Hedge Fund Holders: 31

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most undervalued growth stocks to buy, according to analysts. On March 12, Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced the appointment of David Ramsay as the interim Chief Financial Officer, pending the appointment of a permanent CFO.

Ramsay takes over as CFO with over 30 years of experience in strategic financial leadership across the biotechnology and life sciences sectors. He also boasts of extensive experience in capital markets, corporate finance, and investor relations. He previously served as the company’s CFO from 2003 to 2009 and again from 2013 to 2015. During his tenure, the company evolved from a private company to a billion-dollar entity.

Earlier on March 11, Halozyme Therapeutics outlined its growth strategy at The Citizens Life Sciences Conference, projecting $1.7–$1.8 billion in revenue for the year, a 22%–30% increase. CEO Helen Torley emphasized the strength of ENHANZE drug‑delivery royalties, expected to reach $1.1–$1.2 billion, alongside contributions from products like DARZALEX FASPRO and VYVGART HYTRULO. Despite ongoing patent litigation with Merck, Halozyme sees royalties unaffected and plans at least three new deals in 2026.

Financially, adjusted EBITDA is forecast at $1.1–$1.2 billion, supported by acquisitions such as Elektrofi and Surf Bio, which enhance its Hypercon technology portfolio. With seven ENHANZE products in development and multiple trials starting this year, Halozyme aims to have 40 drugs approved or in development by 2028, positioning ENHANZE and Hypercon as long‑term growth drivers.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biotechnology company focused on developing and commercializing disruptive drug delivery technologies, primarily using its proprietary ENHANZE® technology. The technology uses recombinant human hyaluronidase (rHuPH20) to enable rapid, high-volume subcutaneous injection of drugs typically administered intravenously.

2. Pan American Silver Corp. (NYSE:PAAS)

Stock Upside Potential: 46.38%

Forward P/E: 8.48

Number of Hedge Fund Holders: 38

Pan American Silver Corp. (NYSE:PAAS) is one of the most undervalued growth stocks to buy, according to analysts. On March 24, Pan American Silver Corp. (NYSE:PAAS) outlined plans to transform its La Colorada property in Zacatecas, Mexico, into the world’s largest silver operation.

The company is planning a $1.9 billion expansion drive, having identified high-grade veins and portions of the skarn deposit at the La Colorada mine. The company expects the mine to evolve into one of the largest and lowest-cost silver mines, with silver production averaging 19.1 million ounces during the peak five years.

Part of the expansion plan entails the construction of a new 15,000 tons per day processing plant while operating the existing vein mine. Pan American Silver Corp also targets a 37-year mine life following plant construction. The $1.9 billion in capital costs is to be spread over six years, from 2026 to 2031,with the company planning to fund the project from existing operations.

Pan American Silver Corp. (NYSE:PAAS) is a premier Canadian-based mining company that explores, extracts, and produces silver and gold, along with base metals like zinc, lead, and copper, primarily in the Americas. It operates high-margin mines and aims to be the world’s leading silver producer, with operations in Canada, Mexico, Brazil, Argentina, and Peru.

1. Coeur Mining, Inc. (NYSE:CDE)

Stock Upside Potential: 48.61%

Forward P/E: 11.63

Number of Hedge Fund Holders: 51

Coeur Mining, Inc. (NYSE:CDE) is one of the most undervalued growth stocks to buy, according to analysts. On March 23, Cantor Fitzgerald upgraded Coeur Mining, Inc. (NYSE:CDE) to a Buy from a Hold and lowered the price target to $20 from $24.

The research firm upgraded the stock following a recent share price pullback. The new price target is in response to the company’s 2026 guidance on mine-life extensions, dividends, and buyback policies. For 2025, the company reported revenue of $2.1 billion and net income from continuing operations of $493 million. It expects 2026 gold and silver production of 390,000-460,000 ounces and 18.2-21.3 million ounces, respectively. On a combined basis, it expects $3 billion of EBITDA and $2 billion of free cash flow.

Earlier on March 20, Coeur Mining announced that it had completed the acquisition of New Gold Inc. The acquisition is poised to result in a leading North American-based precious metals producer. Consequently, it remains well positioned to produce between 680,000 and 815,000 ounces of gold, 18.7 to 21.9 million ounces of silver, and 50 to 65 million pounds of copper.

Coeur Mining, Inc. (NYSE:CDE) is a U.S.-based, well-diversified, and growing precious metals producer with a focus on exploring, developing, and operating gold and silver assets in North America. The company operates several key mines, including the Rochester mine in Nevada and the Palmarejo complex in Mexico, and is strategically focused on expanding its portfolio of high-grade assets.

READ NEXT: 10 Robinhood Stocks with High Potential and 10 Popular Penny Stocks on Robinhood to Buy.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.